Product Description
Mechanisms of Action: FOLR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Ovarian Cancer
Phase 2: Non-Small-Cell Lung Cancer|Breast Cancer|Adenocarcinoma|Carcinoma, Adenosquamous|Squamous Cell Carcinoma|Endometrial Cancer|Ovarian Cancer|Triple Negative Breast Cancer
Phase 1: Oncology Solid Tumor Unspecified|Endometrial Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-8109-004 | P2 |
Withdrawn |
Breast Cancer |
2016-11-01 |
|
| Vintafolide and vintafolide plus paclitaxel compared to paclitaxel alone in subjects with TNBC using | P2 |
Terminated |
Triple Negative Breast Cancer |
2016-03-23 |
|
| PROCEED | P3 |
Terminated |
Ovarian Cancer |
2015-10-17 |
|
| TARGET NSCLC:Trial to Assess benefit of folate-Receptor tarGEteted Treatment of second-line NSCLC | P2 |
Completed |
Adenocarcinoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Carcinoma, Adenosquamous |
2015-06-01 |